CompletedPhase 2/3

ENAC Blockade and Arterial Stiffness

United States137 participantsStarted 2019-07-15

Plain-language summary

To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.

Who can participate

Age range30 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. History of type 1 or type 2 diabetes
✕. Known cardiovascular events within the last 12 months (stroke, acute coronary event, revascularization, heart failure hospitalization).
✕. History of uncontrolled thyroid disease, chronic liver disease (cirrhosis) or GFR \<50 ml/min.
✕. Use of potassium sparing medications (angiotensin II receptor blockers, angiotensin converting enzymes inhibitors or mineralocorticoid receptor blockers) or use of potassium supplements.
✕. Active cancer (This criterion does not apply to those subjects with basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
✕. Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
✕. Current tobacco use
✕. Non controlled hypertension

What they're measuring

Carotid Femoral Pulse Wave Velocity

Timeframe: baseline, 3 and 6 mo

Trial details

NCT IDNCT03837626

SponsorUniversity of Missouri-Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-05

Results submitted2025-09-30

View on ClinicalTrials.gov More Overweight and Obesity trials